Rights and permissions
About this article
Cite this article
Erlotinib marginally cost effective for NSCLC. Pharmacoecon. Outcomes News 601, 7 (2010). https://doi.org/10.2165/00151234-201006010-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201006010-00015